Redx is a UK biotechnology Group whose shares are traded on AIM ( AIM:REDX ). Redx is focused on creating and developing first, or potentially best in class drugs, in specific areas of cancer and fibrosis that address significant unmet medical need. Redx has an in-house discovery team with proven world-class chemistry capabilities.


Tom Burt

Tom joined Sofinnova in June 2017 from Peel Hunt where he is senior research analyst in Healthcare & Life Sciences. Tom has 11 years of experience in life sciences venture and private company investing, equity and alternative financing (hybrid and debt instruments). He has worked for several years with ...